Massimo Cugno
About
In The Last Decade
Massimo Cugno
210 papers receiving 8.4k citations
Hit Papers
Peers
Comparison fields: 5 of 124
- Genetics 3.9k
- Rheumatology 3.2k
- Pathology and Forensic Medicine 2.3k
- Immunology 2.2k
- Hematology 1.4k
Countries citing papers authored by Massimo Cugno
This map shows the geographic impact of Massimo Cugno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Massimo Cugno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Massimo Cugno more than expected).
Fields of papers citing papers by Massimo Cugno
This network shows the impact of papers produced by Massimo Cugno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Massimo Cugno. The network helps show where Massimo Cugno may publish in the future.
Co-authorship network of co-authors of Massimo Cugno
This figure shows the co-authorship network connecting the top 25 collaborators of Massimo Cugno. A scholar is included among the top collaborators of Massimo Cugno based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Massimo Cugno. Massimo Cugno is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 8 | |
| 2 | 3 | |
| 3 | 22 | |
| 4 | 3 | |
| 5 | 4 | |
| 6 | 32 | |
| 7 | 103 | |
| 8 | Prothrombotic biomarkers in patients with rheumatoid arthritis: the beneficial effect of IL-6 receptor blockade. | 26 |
| 9 | 96 | |
| 10 | 26 | |
| 11 | 12 | |
| 12 | 19 | |
| 13 | 40 | |
| 14 | 40 | |
| 15 | 24 | |
| 16 | Effects of recombinant human activated protein C on the fibrinolytic system of patients undergoing conventional or tight glycemic control. | 5 |
| 17 | 24 | |
| 18 | 27 | |
| 19 | 146 | |
| 20 | Efficiacy of C1-inhibitor plasma concentrate, the main kallikrein inactivator, in preventing hyperamylasemia induced by endoscopic papillosphincterotomy | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.